The goal of this article is to review the current management options for Peyronie’s disease (PD), focusing on the acute phase of the disease. Additionally, we aim to highlight the most recent literature on the subject. Contemporary studies suggest that there are promising novel therapies on the horizon for acute phase PD, such as topical H-100 gel and intralesional interferon-α2b and mycophenolate mofetil. Recent findings also suggest that intralesional collagenase Clostridium histolyticum (CCH) may be effective for the acute phase of PD, in addition to its conventional use in the chronic phase. A variety of treatments have been proposed for PD, with more recent literature focusing on the acute phase. Novel topical therapies are on the horizon and may show promise. External mechanical therapies have shown clinically meaningful changes. CCH may have efficacy during the acute phase of PD. Other intralesional therapies are promising but still require additional large studies to confirm efficacy. Future research on the acute phase of PD may expand treatment options and impact disease management.